Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

Growth Hormone and Chromosome 18q- and Abnormal Growth

NCT00134420 · View on ClinicalTrials.gov ↗

Study Summary

We, the investigators at the University of Texas Health Science Center at San Antonio, want to learn if height and IQ (intelligence quotient) scores are improved by growth hormone (GH) treatment in children with chromosome 18 deletions and abnormal growth. Data from a previous study showed that growth hormone improved height in all children with 18q- and growth hormone deficiency. In addition, most of the study participants on growth hormone treatment showed an increase in IQ scores.

Interventions

  • DRUG Nutropin AQ
  • PROCEDURE Arginine and Clonidine Stimulation Testing
  • PROCEDURE Growth Factors Laboratory Testing
  • PROCEDURE Neuropsychological Testing

Study Locations (1)

Texas

  • The University of Texas Health Science Center at San Antonio — San Antonio

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2001-02
Est. Completion 2005-06
Phase Phase 3

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00134420

The ClinicalTrials.gov registry entry for NCT00134420 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 481 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Growth Hormone Deficiency appearing as the primary indexed condition, and to 4 interventions — of which Nutropin AQ is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00134420 reports 1 study location spanning 1 distinct geographic area — top geographies include Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00134420 about?

NCT00134420 is a clinical study titled "Growth Hormone and Chromosome 18q- and Abnormal Growth". We, the investigators at the University of Texas Health Science Center at San Antonio, want to learn if height and IQ (intelligence quotient) scores are improved by growth hormone (GH) treatment in children with chromosome 18 deletions and abnormal growth. Data from a previous study showed that grow...

What is the current status of trial NCT00134420?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2001-02. Estimated completion is 2005-06.

What conditions does trial NCT00134420 study?

This clinical trial studies the following conditions: Growth Hormone Deficiency, Loss of Chromosome 18q. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00134420?

The interventions under investigation include: Nutropin AQ (DRUG), Arginine and Clonidine Stimulation Testing (PROCEDURE), Growth Factors Laboratory Testing (PROCEDURE), Neuropsychological Testing (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00134420?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 481 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00134420 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial